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Hepatocellular carcinomaAbstract This study was carried out in order to investigate the possible inhibitory effect of camel
milk (CM) on induced hepatocarcinogenesis in rats. Twenty-eight male rats were assigned into 4
groups (7 rats per group). Group I served as control negative. Group II treated with camel milk.
Group III was injected I/P with diethylnitrosamine (DENA) (200 mg/kg) as a single dose and after
one week received 500 ppm phenobarbitone in drinking water. Group IV injected with DENA as
group III and treated with camel milk. Estimation of AST, ALT, albumin, total protein and alpha
fetoprotein (AFP) in the serum of euthanized rats was performed. Histopathological examination
and immunohistochemical staining of AFP and placental glutathione s transferase of the liver were
carried out. Biochemical result at 38th week revealed an increase in serum AFP and a decrease in
serum albumin on group III although no signiﬁcance was detected. Histopathologically, the size of
altered hepatic foci was smaller in the milk treated group (group IV). The number of mitotic ﬁgures
observed in group IV was lower than group III. Hepatocellular carcinoma developed only in group
III but not group IV. Immunohistochemical staining of AFP demonstrated an intense positive
staining in group III and a weak positive staining in group IV. Similarly, the area percent of pre-
neoplastic P-GST positive foci in liver was higher in group III than group IV. In conclusion, camel
milk halted the progression of hepatocellular carcinoma.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Veterinary Medicine, Cairo
University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).1. Introduction
Hepatocellular carcinoma (HCC) which is considered as pri-
mary cancer of liver remains the ﬁfth common cancer and
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occurrence of HCC has been reported in several regions of the
world such as Asia, sub-Saharan Africa, as well as parts of
Europe and the North American continent [2]. Over the past
decade, there was a progressive increase in the incidence of
HCC among chronic liver disease patients in Egypt [3]. Many
risk factors such as inﬂammation have been incriminated in the
occurrence of HCC [4].
Diethylnitrosamine (DEN) is a potent hepatocarcinogen
that, at low doses, acts only as an initiating agent in the rat
liver [5] but when its combined with a promoting agent such
as phenobarbital, development and progression of experimen-
tal liver cancer takes place as reported in the past 2 decades [6].
Many side effects have been associated with chemotherapy for
cancer and the therapeutic outcome remains very poor [7].
Currently, camel milk has been used as a traditional medi-
cine in Egypt in order to treat cancer and HCV infected
patients. Camel milk contains numerous proteins in which
caseins account for 80% (w/w) of the total milk protein
content [8] and whey contains numerous proteins such as
immunoglobulins, a-lactalbumin, lactoperoxidase, lysozyme
and lactoferrin, among other proteins with biological functions
[9]. In addition it contains the whey acidic protein [10] which is
not found in ruminant or primate milk [11]. A wide range of
biological activities have been exhibited by camel milk includ-
ing antimicrobial, antioxidative, antithrombotic, antihyperten-
sive, and immuno-modulatory effect [12,13].
Several studies have investigated the effect of camel milk
and its constituents on tumor cell lines [14] and provided hope-
ful results. Therefore it was important to investigate the possi-
ble anti tumor potential of camel milk in vivo as well.2. Materials and methods
2.1. Animals
Twenty-eight male Wister rats, weighing 100–120 g, were pur-
chased from the animal house of the National Research Center
(El Dokki, El Giza, Egypt). This experimental work was
approved by Ethics of Animal Use in Research Committee
(EAURC), Faculty of Veterinary Medicine, Cairo University,
Egypt. The animals were housed in metal wire mesh cages (4–5
rats per cage) and were left for two weeks before beginning the
experiment for acclimatization. The housing conditions includ-
ing temperature 25 ± 2 C, relative humidity 50–60%, and
12 h photoperiods were set. The rats were supplied with a pel-
leted diet and water ad libitum.
2.2. Chemicals
Diethyl nitrosamine (DENA) was purchased from Sigma
Chemical Co. (St. Louis, MO, USA). Phenobarbitone was
kindly supplied by the Egyptian International Pharmaceutical
Industry Co. (EIPICO).
2.3. Camel milk
Camel milk of Camelus dromedarius was purchased from Ibn
Sina camel farm (Ras sedr, South of Sinai, Egypt) and was
transferred frozen to our laboratory.2.4. Experimental design
28 male rats were divided into four groups (7 rats each).
Group I: served as a negative control group.
Group II: was treated with camel milk 5 ml by oral intuba-
tion after 28 weeks of experimental commence.
Group III: was injected intraperitoneally with a single dose
(200 mg/kg body weight) of diethylnitrosamine dissolved in
saline to initiate hepatocarcinogenesis. After one week, pheno-
barbitone was added to drinking water at a concentration of
0.05% (500 ppm) for 27 weeks.
Group IV: was treated as group III followed by treatment
with camel milk after 28 weeks.
Three rats from each group were then euthanized after
34 weeks of DENA injection (6 weeks of camel milk treat-
ment). The rest of the rats were euthanized after 38 weeks
(9 weeks of CM treatment).
2.5. Biochemical analysis
Serum AST, ALT, albumin and total protein were analyzed
spectrophotometrically using commercially available kits
(spectrum, Egypt). Estimation of serum AFP was also carried
out using rat alpha-fetoprotein ELISA kit (WKEA Med
supplies corp., China).
2.6. Histopathology
Liver samples were ﬁxed for 48 h in 10% neutral buffered for-
malin and processed by parafﬁn embedding technique. Sec-
tions of 5–6 lm thick were prepared and stained with H&E
stain for microscopic examination [15]. Liver specimens from
three different lobes were examined for each rat and lesion
score for altered hepatocellular foci was performed. Diagnosis
of liver cell foci and neoplasms was performed according to the
histological criteria of the Institute of Laboratory Animal
Resources [16] on the hematoxylin and eosin-stained sections.
The mean area of foci was measured in group III and IV using
image analyzer Leica Quin 500 (Pathology department, NRC).
2.7. Immunohistochemical detection of Alfa Fetoprotein
Liver parafﬁn tissue sections were stained by immunoperoxi-
dase technique using anti alpha fetoprotein antibody (Pierce
Biotech., USA) and the avidin biotin peroxidase complex
method (UltraVision Detection System Anti-Mouse, HRP/
DAB, Lab Vision Corp., USA). 3,3-diaminobenzdine (DAB)
was used for color development. All staining procedure was
carried out according to manufacturer protocol. The optical
density of immunohistochemically stained AFP was measured
using image analyzer Leica Quin 500, Pathology department,
NRC.
2.8. Immunohistochemical staining of placental glutathione
s transferase
Parafﬁn embedded liver tissue sections were immunohisto-
chemically stained by using Anti-GST-P polyclonal antibody
prepared in rabbit (MBL Co., LTD, USA) and the avidin bio-
tin peroxidase complex method according to kit manufacturer
protocol (Dako, LSAB + system-HRP, North America, Inc.).
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measured using image analyzer Leica Quin 500, Pathology
department, NRC.
2.9. Statistical analysis
Statistical analysis was carried out using statistical package
SPSS, version 8.0 (SPSS Inc., Chicago, IL, USA). Statistical
analysis of data was carried out using one-way analysis of var-
iance (ANOVA) followed by LSD and Duncan test. Results
were expressed as mean ± standard error (mean ± SE). P val-
ues less than 0.05 were considered signiﬁcant.
3. Results
3.1. Biochemical analysis
At the 34th week, there was no signiﬁcant difference in total
protein, albumin, ALT, AST and AFP between groupsFigure 1 Photomicrograph of liver showing (A) clear cell hepato
carcinoma with multiple mitotic ﬁgures (arrows) at 38th week in group
(D) focal area of necrosis with inﬂammatory cell inﬁltration (X 200) i
Table 1 Levels of serum variables after 34 and 38 weeks of DENA
Group Total protein (g/dl) Albumin (
I 34 W 11.49 ± 1.12 4.33 ± 0.2
38 W 10.26 ± 1.0 3.1 ± 0.2
II 34 W 11.5 ± 1.9 4.39 ± 0.1
38 W 10.07 ± 0.6 3.4 ± 0.2
III 34 W 10.5 ± 1.5 4.33 ± 0.0
38 W 14.64 ± 0.008 2.5 ± 0.0
IV 34 W 7.78 ± 0.4 4.36 ± 0.1
38 W 10.47 ± 1.79 3.2 ± 0.3
Values were represented as mean ± SE (n = 3–4).
* Indicate signiﬁcant difference at P < 0.05.(Table 1). However, there was a signiﬁcant increase in ALT
in group IV at 38th week compared to other groups. The
serum albumin was low and AFP was high in group III at
38th week although no signiﬁcant difference has been detected.
3.2. Histopathology
The liver of rats treated with DENA exhibited different degen-
erative changes taking the form of cytoplasmic vacuolation
progressing into single cell necrosis and foci of necrosis with
few inﬂammatory cells inﬁltration. The cellular necrosis leaded
to hepatic dissociation and sinusoidal dilatation. Portal area
showed biliary hyperplasia and collagen deposition. In addi-
tion, to the previous histological picture, altered hepatocellular
foci including clear cell, eosinophilic and basophilic foci were
observed. At the 34th week, large clear hepatocellular ade-
noma with multiple mitotic divisions at the periphery was evi-
dent. It was well demarcated by compression of the adjacent
tissue and altered staining properties (Fig. 1A). At 38th week,
the number and size of altered hepatocellular foci and thecellular adenoma at 34th week (X 100) and (B) hepatocellular
III (B X 1000), (C) focus of hepatocellular alteration (X 100) and
n group IV. (H and E stain.)
injection.
g/dl) ALT (U/L) AST (U/L) AFP (lg/l)
4 23.6 ± 1.3 23.3 ± 4.3 2.17 ± 0.008
4 14.5 ± 2.8 39 ± 7.9 0.58 ± 0.23
23.6 ± 1.3 37.6 ± 2.8 1.42 ± 0.23
5 26.25 ± 5.2 19.5 ± 5.8 1.2 ± 0.005
5 22.3 ± 1.3 30.3 ± 11 2.16 ± 0.61
05 21 ± 2.3 24 ± 6.65 1.45 ± 0.34
6 21 ± 0.0 38.5 ± 16.6 0.54 ± 0.34
3 32.7 ± 1.25* 34.5 ± 8.83 1.01 ± 0.24
Figure 2 Chart showing the mean area of hepatocellular altered
foci in group III and group IV.
Figure 4 Chart showing the optical density of immunohisto-
chemically stained AFP in ten high power microscopic ﬁelds.
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obviously increased compared to those observed at 34th week.
Moreover, hepatocellular adenoma and hepatocellular
carcinoma were demonstrated (Fig. 1B).
On the other hand, liver of rats in group IV at 34th week
showed focal areas of microvesicular steatosis but in overall
there was less cytoplasmic vacuolation compared to group
III. Minute foci of necrosis associated with mononuclear
inﬂammatory cell inﬁltration and foci of hepatocellular altera-
tions were evident (Fig. 1C and D). At 38th week, few sporadic
cell necrosis and apoptotic bodies were observed. Based on the
lesion score performed, the number and size of hepatocellular
altered foci was lesser than those detected in group III and
there was only one small eosinophilic hepatocellular adenoma
(Fig. 2).
3.3. Immunohistochemical detection of AFP
Alfa Fetoprotein stained positive in group III and group IV as
seen in Fig. 3. Brown granules of alpha fetoprotein wereFigure 3 Photomicrograph of rat liver showing immunostaining of A
(arrow) in group III and (D) weak positive cells (arrow) in group IVevident in the cytoplasm of hepatocytes. Never the less, the
optical density of staining intensity measured by image ana-
lyzer increased in group III than group IV (Fig. 4).
3.4. Immunohistochemical staining of P-GST
Multiple foci of brown positive reaction in hepatic tissue rep-
resenting enzyme altered foci have been demonstrated in group
III and group IV at 34th week and 38th week post injection
whereas group I and group II showed negative staining for
P-GST. Remarkably, there was a variation in size and number
of these enzyme altered foci. Large strongly positive enzyme
altered foci were detected in group III. On the other hand,
group IV showed small and moderate sized foci of positively
stained enzyme altered foci. This variation was clearer at
38th week post injection than at 34th week. The mean area
percent of enzyme altered foci in different groups at 34th
and 38th week which was measured by image analysis is dem-
onstrated in (Fig. 5).FP (A) negative staining in group I, (B and C) strong positive cells
(IP X 400).
Figure 5 Chart showing the mean area percent and count/area of enzyme altered foci (P-GST positive).
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DENA acting through a variety of mechanisms such as DNA
alkylation [17] and free radical generation [18] induces hepato-
carcinogenesis. Number of investigations is being carried out
to discover natural products that can interrupt the carcinogen-
esis process [19,20]. DENA was found to elevate the activities
of liver speciﬁc enzymes AST and ALT and also total bilirubin
[21] which however disagreed with the current study in which
there was no elevation detected at 34th week. The time elapse
between the DENA injection and the serum analysis might be
the factor for such insigniﬁcance.
Although, serum level of alpha fetoprotein (AFP) showed
insigniﬁcant difference between groups at 34th and 38th week,
group III showed a relative elevation and a strong positive
immunohistochemical staining for AFP. Alpha fetoprotein
was found to contribute somehow in hepatocellular prolifera-
tion and for that reason it was considered as a liver tumor
marker [22,23].
Increased collagen deposition in the portal area was evident
in group III which agrees with previous research work [24–25].
Liver injury induced by chemicals such as nitrosamines can
proceed to hepatic vacuolization, necrosis, ﬁbrosis, bile duct
or hepatocyte hyperplasia and neoplasia [26]. In this respect,
the present study, recorded decrease in mononuclear inﬂam-
matory cell inﬁltration, hyperplasia of bile duct epithelium
and ﬁbrosis in group IV which is in accordance with Darwish
et al. [27], who pointed out that decreased degeneration of
some hepatocytes as well as reduced collagen accumulation
following the CM feeding to rats with ethanol induced liver
injury were evident.
Several studies have been conducted on the relation
between the expression of placental glutathione transferases
and hepatocarcinogenesis [28–29]. The initiation potential of
several carcinogens has been demonstrated by the induction
of preneoplastic glutathione-s-transferase P-form positive liver
cell foci [30].
Hepatoprotection due to feeding on camel milk has been
previously documented by Shamanov et al., [31] who indicated
that patients with chronic active hepatitis showed positive
shifts in the clinical and laboratory ﬁndings after beingsupplemented with whole camel milk. The anti tumor effect
of camel milk presented in this study can be attributed to its
antioxidant properties and scavenging effects on free radicals.
CM was found to contain high concentrations of vitamins A,
B2, C and E [32]. These vitamins act as antioxidants and have
been effective in preventing toxicant-induced tissue injury [33].
A recent work have shown the ability of camel milk to
signiﬁcantly inhibit the induction of the cytochrome
P4501A1 (Cyp1a1), a cancer-activating gene, and to induce
the NAD(P)H: quinone oxidoreductase 1 (NQO1), cancer che-
mopreventive gene in murine hepatoma Hepa 1c1c7 cells at the
transcriptional and posttranscriptional levels [34]. Camel milk
was found to cease tumor cell lines (HepG2 and MCF7 cells)
survival and proliferation through the activation of both the
extrinsic and intrinsic apoptotic pathways [35]. Several milk
proteins were incriminated in the apoptotic potential of camel
milk including camel casein and lactoferrin. Camel casein was
reported to induce apoptosis and in turn reduce the viability of
tumor cell lines [14]. Lactoferrin as well which is found in high
concentration in camel milk [36], was thought to cause apopto-
sis of tumor cells by the activation of the Fas signaling path-
way. However the exact mechanism has not yet been
discovered [37].5. Conclusion
Camel milk protected the liver against toxicity induced by
DENA, prevented the development of hepatocellular carci-
noma and halted the growth of hepatocellular altered foci.References
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